Toll Free: 1-888-928-9744

Atopic Dermatitis - Pipeline Review, H1 2016

Published: Feb, 2016 | Pages: 351 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Atopic Dermatitis - Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Atopic dermatitis - Pipeline Review, H1 2016', provides an overview of the Atopic dermatitis pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Atopic dermatitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Atopic dermatitis and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Atopic dermatitis
- The report reviews pipeline therapeutics for Atopic dermatitis by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Atopic dermatitis therapeutics and enlists all their major and minor projects
- The report assesses Atopic dermatitis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Atopic dermatitis

Reasons to Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Atopic dermatitis
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Atopic dermatitis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
 Table of Contents
Table of Contents 2
List of Tables 7
List of Figures 9
Introduction 10
Global Markets Direct Report Coverage 10
Atopic Dermatitis Overview 11
Therapeutics Development 12
Pipeline Products for Atopic Dermatitis - Overview 12
Pipeline Products for Atopic Dermatitis - Comparative Analysis 13
Atopic Dermatitis - Therapeutics under Development by Companies 14
Atopic Dermatitis - Therapeutics under Investigation by Universities/Institutes 20
Atopic Dermatitis - Pipeline Products Glance 21
Late Stage Products 21
Clinical Stage Products 22
Early Stage Products 23
Unknown Stage Products 24
Atopic Dermatitis - Products under Development by Companies 25
Atopic Dermatitis - Products under Investigation by Universities/Institutes 32
Atopic Dermatitis - Companies Involved in Therapeutics Development 33
Abeome Corporation 33
Accolade Pharmaceuticals, LLC 34
AlbireoPharma 35
Almirall, S.A. 36
Amgen Inc. 37
Amorepacific Corporation 38
Anacor Pharmaceuticals, Inc. 39
AnaMar AB 40
AnaptysBio, Inc. 41
AnGes MG, Inc. 42
Aquinox Pharmaceuticals Inc. 43
arGEN-X BV 44
Blueberry Therapeutics Ltd 45
Brickell Biotech, Inc. 46
Celgene Corporation 47
ChemoCentryx, Inc. 48
ChironWells GmbH 49
Chugai Pharmaceutical Co., Ltd. 50
Creabilis SA 51
Delenex Therapeutics AG 52
Dermira Inc. 53
Dr. August Wolff GmbH & Co. KG Arzneimittle 54
Eli Lilly and Company 55
F. Hoffmann-La Roche Ltd. 56
Foamix Pharmaceuticals Ltd. 57
Fountain Biopharma Inc. 58
GlaxoSmithKline Plc 59
Glenmark Pharmaceuticals Ltd. 60
Grupo Ferrer Internacional, S.A. 61
Han Wha Pharma Co., Ltd. 62
HanAll Biopharma Co., Ltd. 63
Herantis Pharma Plc 64
Immune Pharmaceuticals Inc. 65
Inflamalps SA 66
Japan Tobacco Inc. 67
Johnson & Johnson 68
Kineta, Inc. 69
LegoChem Biosciences, Inc 70
LEO Pharma A/S 71
Madam Therapeutics B.V. 72
MedImmune, LLC 73
NeoPharm Co., Ltd. 74
Novan, Inc. 75
Novartis AG 76
Orbis Biosciences, Inc. 77
Otsuka Holdings Co., Ltd. 78
Oxagen Limited 79
Pfizer Inc. 80
Pharis Biotec GmbH 81
Pharmedartis GmbH 82
Provectus Biopharmaceuticals, Inc. 83
Regeneron Pharmaceuticals, Inc. 84
Signum Dermalogix, Inc 85
Spherium Biomed S.L. 86
sterna biologicals Gmbh & Co KG 87
Sucampo Pharmaceuticals, Inc. 88
Sun Pharma Advanced Research Company Ltd. 89
SWITCH Biotech LLC 90
Takeda Pharmaceutical Company Limited 91
Thesan Pharmaceuticals, Inc. 92
Valeant Pharmaceuticals International, Inc. 93
Vicore Pharma AB 94
Vitae Pharmaceuticals, Inc. 95
VivaCell Biotechnology Espana S.L. 96
Xencor, Inc. 97
Ziarco Pharma Ltd 98
Atopic Dermatitis - Therapeutics Assessment 99
Assessment by Monotherapy Products 99
Assessment by Target 100
Assessment by Mechanism of Action 105
Assessment by Route of Administration 109
Assessment by Molecule Type 111
Drug Profiles 113
A-3914 - Drug Profile 113
A-5425 - Drug Profile 114
AKP-11 - Drug Profile 115
ALX-101 - Drug Profile 117
AM-1030 - Drug Profile 118
AN-4161 - Drug Profile 119
ANB-020 - Drug Profile 120
apremilast - Drug Profile 121
Aptamers to Inhibit Galectin-3 for Atopic Dermatitis - Drug Profile 124
AQX-1125 - Drug Profile 125
ARGX-112 - Drug Profile 128
ARN-077 - Drug Profile 129
baricitinib - Drug Profile 130
BB-2702 - Drug Profile 133
BBI-2000 - Drug Profile 134
BBI-5000 - Drug Profile 135
bertilimumab - Drug Profile 136
Biologic for Atopic Dermatitis and Eczema - Drug Profile 138
C-21 - Drug Profile 139
CBP-174 - Drug Profile 141
CBP-201 - Drug Profile 142
CCX-6239 - Drug Profile 143
CDE-001 - Drug Profile 144
Cis-Urocanic Acid - Drug Profile 145
CNTO-7160 - Drug Profile 148
cobamamide - Drug Profile 149
crisaborole - Drug Profile 150
CT-101 - Drug Profile 152
CT-1x1 - Drug Profile 153
CT-1x2 - Drug Profile 154
CT-1x3 - Drug Profile 155
CT-327 - Drug Profile 156
CT-340 - Drug Profile 158
cyclosporine - Drug Profile 159
dalazatide - Drug Profile 160
DMT-210 - Drug Profile 162
DRM-02 - Drug Profile 163
Drug for Atopic Dermatitis - Drug Profile 164
Drugs to Antagonize TNFR-1 for Atopic Dermatitis - Drug Profile 165
dupilumab - Drug Profile 166
FB-825 - Drug Profile 169
fevipiprant - Drug Profile 170
FIB-116 - Drug Profile 172
Furestem-AD - Drug Profile 173
GBR-830 - Drug Profile 174
Histimex - Drug Profile 175
HS-378 - Drug Profile 176
JTE-052 - Drug Profile 177
KPI-150 - Drug Profile 178
LCB-030110 - Drug Profile 179
lebrikizumab - Drug Profile 180
LEKTI-6 - Drug Profile 182
LEO-32731 - Drug Profile 183
LEO-39652 - Drug Profile 184
mepolizumab - Drug Profile 185
MLR-1130 - Drug Profile 188
mometasone furoate - Drug Profile 189
Monoclonal Antibodies to Inhibit IL-25 for Asthma, Fibrosis and Atopic Dermatitis - Drug Profile 190
Monoclonal Antibody to Inhibit IL-4 and IL-13 for Atopic Dermatitis - Drug Profile 191
Monoclonal Antibody to Target Th22 cell/IL-22 pathway for Inflammatory Bowel Diseases, Atopic Dermatitis and Colorectal Cancer - Drug Profile 192
N-oleoylethanolamine - Drug Profile 193
nemolizumab - Drug Profile 194
NPH-12 - Drug Profile 195
OC-000459 - Drug Profile 196
OC-2417 - Drug Profile 198
octenidine hydrochloride - Drug Profile 199
OLX-103 - Drug Profile 200
omiganan pentahydrochloride - Drug Profile 201
OPA-15406 - Drug Profile 203
P-10 - Drug Profile 204
PAC-14028 - Drug Profile 205
PDI-192 - Drug Profile 207
Peptide to Antagonize CX3CR1 for Atopic Dermatitis - Drug Profile 208
Peptides to Antagonize TNFR-1 for Atopic Dermatitis - Drug Profile 209
PH-10 - Drug Profile 210
PL-601 - Drug Profile 212
PMA-101R - Drug Profile 213
PMA-201 - Drug Profile 214
PMA-411R - Drug Profile 215
prednisone - Drug Profile 216
PZ-235 - Drug Profile 217
Q-301 - Drug Profile 218
Qi-507 - Drug Profile 219
roflumilast - Drug Profile 220
RTU-1096 - Drug Profile 223
RVT-501 - Drug Profile 224
S-414114 - Drug Profile 225
SB-011 - Drug Profile 227
SB-414 - Drug Profile 228
SIG-1311 - Drug Profile 229
SIG-1322 - Drug Profile 231
Small Molecule to Modulate S1PR1 for Atopic Dermatitis - Drug Profile 232
Small Molecules for Atopic Dermatitis - Drug Profile 233
SP-14019 - Drug Profile 234
SUN-0597 - Drug Profile 235
SWT-01113 - Drug Profile 237
SWT-05141 - Drug Profile 238
Synthetic Peptides to Inhibit Kallikrein for Immunology, Dermatological and Genetic Disorders - Drug Profile 239
tacrolimus - Drug Profile 240
tezepelumab - Drug Profile 241
tofacitinib - Drug Profile 243
tralokinumab - Drug Profile 247
ustekinumab - Drug Profile 249
VTP-38543 - Drug Profile 252
WBI-1001 - Drug Profile 253
WOL-071007 - Drug Profile 255
XmAb-7195 - Drug Profile 256
YJC-10592 - Drug Profile 257
Zafi-1 - Drug Profile 258
ZPL-3893787 - Drug Profile 259
ZPL-5212372 - Drug Profile 260
Atopic Dermatitis - Recent Pipeline Updates 261
Atopic Dermatitis - Dormant Projects 324
Atopic Dermatitis - Discontinued Products 334
Atopic Dermatitis - Product Development Milestones 336
Featured News & Press Releases 336
Appendix 342
Methodology 342
Coverage 342
Secondary Research 342
Primary Research 342
Expert Panel Validation 342
Contact Us 342
Disclaimer 343
List of Tables
Number of Products under Development for Atopic Dermatitis, H1 2016 20
Number of Products under Development for Atopic Dermatitis - Comparative Analysis, H1 2016 21
Number of Products under Development by Companies, H1 2016 22
Number of Products under Development by Companies, H1 2016 (Contd..1) 23
Number of Products under Development by Companies, H1 2016 (Contd..2) 24
Number of Products under Development by Companies, H1 2016 (Contd..3) 25
Number of Products under Development by Companies, H1 2016 (Contd..4) 26
Number of Products under Development by Companies, H1 2016 (Contd..5) 27
Number of Products under Investigation by Universities/Institutes, H1 2016 28
Comparative Analysis by Late Stage Development, H1 2016 29
Comparative Analysis by Clinical Stage Development, H1 2016 30
Comparative Analysis by Early Stage Development, H1 2016 31
Comparative Analysis by Unknown Stage Development, H1 2016 32
Products under Development by Companies, H1 2016 33
Products under Development by Companies, H1 2016 (Contd..1) 34
Products under Development by Companies, H1 2016 (Contd..2) 35
Products under Development by Companies, H1 2016 (Contd..3) 36
Products under Development by Companies, H1 2016 (Contd..4) 37
Products under Development by Companies, H1 2016 (Contd..5) 38
Products under Development by Companies, H1 2016 (Contd..6) 39
Products under Investigation by Universities/Institutes, H1 2016 40
Atopic Dermatitis - Pipeline by Abeome Corporation, H1 2016 41
Atopic Dermatitis - Pipeline by Accolade Pharmaceuticals, LLC, H1 2016 42
Atopic Dermatitis - Pipeline by AlbireoPharma, H1 2016 43
Atopic Dermatitis - Pipeline by Almirall, S.A., H1 2016 44
Atopic Dermatitis - Pipeline by Amgen Inc., H1 2016 45
Atopic Dermatitis - Pipeline by Amorepacific Corporation, H1 2016 46
Atopic Dermatitis - Pipeline by Anacor Pharmaceuticals, Inc., H1 2016 47
Atopic Dermatitis - Pipeline by AnaMar AB, H1 2016 48
Atopic Dermatitis - Pipeline by AnaptysBio, Inc., H1 2016 49
Atopic Dermatitis - Pipeline by AnGes MG, Inc., H1 2016 50
Atopic Dermatitis - Pipeline by Aquinox Pharmaceuticals Inc., H1 2016 51
Atopic Dermatitis - Pipeline by arGEN-X BV, H1 2016 52
Atopic Dermatitis - Pipeline by Blueberry Therapeutics Ltd, H1 2016 53
Atopic Dermatitis - Pipeline by Brickell Biotech, Inc., H1 2016 54
Atopic Dermatitis - Pipeline by Celgene Corporation, H1 2016 55
Atopic Dermatitis - Pipeline by ChemoCentryx, Inc., H1 2016 56
Atopic Dermatitis - Pipeline by ChironWells GmbH, H1 2016 57
Atopic Dermatitis - Pipeline by Chugai Pharmaceutical Co., Ltd., H1 2016 58
Atopic Dermatitis - Pipeline by Creabilis SA, H1 2016 59
Atopic Dermatitis - Pipeline by Delenex Therapeutics AG, H1 2016 60
Atopic Dermatitis - Pipeline by Dermira Inc., H1 2016 61
Atopic Dermatitis - Pipeline by Dr. August Wolff GmbH & Co. KG Arzneimittle, H1 2016 62
Atopic Dermatitis - Pipeline by Eli Lilly and Company, H1 2016 63
Atopic Dermatitis - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016 64
Atopic Dermatitis - Pipeline by Foamix Pharmaceuticals Ltd., H1 2016 65
Atopic Dermatitis - Pipeline by Fountain Biopharma Inc., H1 2016 66
Atopic Dermatitis - Pipeline by GlaxoSmithKline Plc, H1 2016 67
Atopic Dermatitis - Pipeline by Glenmark Pharmaceuticals Ltd., H1 2016 68
Atopic Dermatitis - Pipeline by Grupo Ferrer Internacional, S.A., H1 2016 69
Atopic Dermatitis - Pipeline by Han Wha Pharma Co., Ltd., H1 2016 70
Atopic Dermatitis - Pipeline by HanAll Biopharma Co., Ltd., H1 2016 71
Atopic Dermatitis - Pipeline by Herantis Pharma Plc, H1 2016 72
Atopic Dermatitis - Pipeline by Immune Pharmaceuticals Inc., H1 2016 73
Atopic Dermatitis - Pipeline by Inflamalps SA, H1 2016 74
Atopic Dermatitis - Pipeline by Japan Tobacco Inc., H1 2016 75
Atopic Dermatitis - Pipeline by Johnson & Johnson, H1 2016 76
Atopic Dermatitis - Pipeline by Kineta, Inc., H1 2016 77
Atopic Dermatitis - Pipeline by LegoChem Biosciences, Inc, H1 2016 78
Atopic Dermatitis - Pipeline by LEO Pharma A/S, H1 2016 79
Atopic Dermatitis - Pipeline by Madam Therapeutics B.V., H1 2016 80
Atopic Dermatitis - Pipeline by MedImmune, LLC, H1 2016 81
Atopic Dermatitis - Pipeline by NeoPharm Co., Ltd., H1 2016 82
Atopic Dermatitis - Pipeline by Novan, Inc., H1 2016 83
Atopic Dermatitis - Pipeline by Novartis AG, H1 2016 84
Atopic Dermatitis - Pipeline by Orbis Biosciences, Inc., H1 2016 85
Atopic Dermatitis - Pipeline by Otsuka Holdings Co., Ltd., H1 2016 86
Atopic Dermatitis - Pipeline by Oxagen Limited, H1 2016 87
Atopic Dermatitis - Pipeline by Pfizer Inc., H1 2016 88
Atopic Dermatitis - Pipeline by Pharis Biotec GmbH, H1 2016 89
Atopic Dermatitis - Pipeline by Pharmedartis GmbH, H1 2016 90
Atopic Dermatitis - Pipeline by Provectus Biopharmaceuticals, Inc., H1 2016 91
Atopic Dermatitis - Pipeline by Regeneron Pharmaceuticals, Inc., H1 2016 92
Atopic Dermatitis - Pipeline by Signum Dermalogix, Inc, H1 2016 93
Atopic Dermatitis - Pipeline by Spherium Biomed S.L., H1 2016 94
Atopic Dermatitis - Pipeline by sterna biologicals Gmbh & Co KG, H1 2016 95
Atopic Dermatitis - Pipeline by Sucampo Pharmaceuticals, Inc., H1 2016 96
Atopic Dermatitis - Pipeline by Sun Pharma Advanced Research Company Ltd., H1 2016 97
Atopic Dermatitis - Pipeline by SWITCH Biotech LLC, H1 2016 98
Atopic Dermatitis - Pipeline by Takeda Pharmaceutical Company Limited, H1 2016 99
Atopic Dermatitis - Pipeline by Thesan Pharmaceuticals, Inc., H1 2016 100
Atopic Dermatitis - Pipeline by Valeant Pharmaceuticals International, Inc., H1 2016 101
Atopic Dermatitis - Pipeline by Vicore Pharma AB, H1 2016 102
Atopic Dermatitis - Pipeline by Vitae Pharmaceuticals, Inc., H1 2016 103
Atopic Dermatitis - Pipeline by VivaCell Biotechnology Espana S.L., H1 2016 104
Atopic Dermatitis - Pipeline by Xencor, Inc., H1 2016 105
Atopic Dermatitis - Pipeline by Ziarco Pharma Ltd, H1 2016 106
Assessment by Monotherapy Products, H1 2016 107
Number of Products by Stage and Target, H1 2016 109
Number of Products by Stage and Mechanism of Action, H1 2016 114
Number of Products by Stage and Route of Administration, H1 2016 118
Number of Products by Stage and Molecule Type, H1 2016 120
Atopic Dermatitis Therapeutics - Recent Pipeline Updates, H1 2016 269
Atopic Dermatitis - Dormant Projects, H1 2016 332
Atopic Dermatitis - Dormant Projects (Contd..1), H1 2016 333
Atopic Dermatitis - Dormant Projects (Contd..2), H1 2016 334
Atopic Dermatitis - Dormant Projects (Contd..3), H1 2016 335
Atopic Dermatitis - Dormant Projects (Contd..4), H1 2016 336
Atopic Dermatitis - Dormant Projects (Contd..5), H1 2016 337
Atopic Dermatitis - Dormant Projects (Contd..6), H1 2016 338
Atopic Dermatitis - Dormant Projects (Contd..7), H1 2016 339
Atopic Dermatitis - Dormant Projects (Contd..8), H1 2016 340
Atopic Dermatitis - Dormant Projects (Contd..9), H1 2016 341
Atopic Dermatitis - Discontinued Products, H1 2016 342
Atopic Dermatitis - Discontinued Products (Contd..1), H1 2016 343 



To request a free sample copy of this report, please complete the form below.

We never share your personal data. Privacy policy
Interested in this report? Get your FREE sample now! Get a Free Sample
Choose License Type
Single User - US $2000
Multi User - US $4000
Hexareeasearch Know

Did you know?

Research Assistance

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Why to buy from us

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Information security

Your personal and confidential information is safe and secure.

verify